A Phase 3 interventional study of GSK573719/GW642444 Inhalation Powder in Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline. Completed at 23 sites in Japan. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2017-01-09.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing GSK573719 in Pulmonary Disease, Chronic Obstructive — 3 open to participants now, 3 under way, none of them phase 3. GSK573719 · Pulmonary Disease, Chronic Obstructive.
Among the 43 studies testing GSK573719 in Pulmonary Disease, Chronic Obstructive, this one is the 22nd largest by enrollment, is one of 8 that started in 2011, is one of 14 in phase 3, and was the 11th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →3 of the 43 studies testing GSK573719 in Pulmonary Disease, Chronic Obstructive are open now, in 3 countries. Recruiting first, the newest first:
Western University, Canada · Sites in Canada
Ages 50–85
University of Tennessee Graduate School of Medicine · Sites in United States
Ages 40+
National Institute of Respiratory Diseases, Mexico · Sites in Mexico
Ages 35–85 · Women only
By country, each count listing its studies:
GSK573719: first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 8 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 131 is above the median of 62 across 3,841 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 131 across the 43 interventional studies. Of the 37 that completed or were terminated, 25 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 43 have an industry lead sponsor. The 9 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline: 7 open now, 8 under way, 5 of them phase 3. Of 264 finished, 141 (53%) have results posted.
Among the 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline, this one is the 109th largest by enrollment of the 236 interventional ones that give a count, is one of 26 that started in 2011, is one of 65 in phase 3, and was the 121st registered.
GlaxoSmithKline’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 2000.
2 of the studies testing GSK573719 in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07133880University of Tennessee Graduate School of MedicineCompare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators | 2026-12-01 |
| NCT07192016Western University, Canada129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 43 studies testing GSK573719 in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 276 in Pulmonary Disease, Chronic Obstructive:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to evaluate the safety and tolerability of GSK573719/GW642444 Inhalation Powder 125/25 mcg once-daily. The product will be delivered via the Novel Dry Powder Inhaler (nDPI) over 52 weeks to Japanese subjects with Chronic Obstructive Pulmonary Disease (COPD). This is a multi-centre, open-label study evaluating the safety of GSK573719/GW642444 Inhalation Powder 125/25 mcg. Treatment will be given once-daily in the morning. The target enrolment is approximately 120 subjects at approximately 20 study centres in Japan. The total duration of subject participation will be 54-55 weeks, consisting of a 7-14 day run-in period, 52-week treatment period and 1-week follow-up period. Subjects meeting all of the inclusion criteria and none of the exclusion criteria at screening visit (Visit 1) will enter 7-14 day run-in period. The run-in period is provided for completion of baseline safety evaluations and to obtain baseline measures of COPD status. At Visit 2, eligible subjects will start to take GSK573719/GW642444 125/25 mcg, and enter the treatment period. This treatment will be delivered via the Novel Dry Powder Inhaler (nDPI) once daily in the morning for 52 weeks. One nDPI will contain 30 doses of study medication. Subjects will be instructed to administer medication once daily in the morning for the duration of the 52-week treatment period. Each subject should be advised to adhere to this dosing regimen throughout the study. There will be a total of 8 study visits including at screening (Visit 1), initiation of treatment (Visit 2), and at 4weeks, 8 weeks, 12 weeks, 24 weeks, 36 weeks, 52 weeks (Visit 3 through Visit 8, respectively). Follow-up (Visit 9) will be conducted by the phone contact approximately 1 week following the completion/withdrawal of treatment period. A subject will be considered to have completed the study upon completion of the last on-treatment visit (Visit 8). At the end of the treatment period, subjects will be prescribed appropriate COPD medication at the investigator's discretion.
The objective of this study is to evaluate the safety and tolerability of GSK573719/GW642444 Inhalation Powder 125/25 mcg once-daily. The product will be delivered via the Novel Dry Powder Inhaler (nDPI) over 52 weeks to Japanese subjects with Chronic Obstructive Pulmonary Disease (COPD). This is a multi-centre, open-label study evaluating the safety of GSK573719/GW642444 Inhalation Powder 125/25 mcg. Treatment will be given once-daily in the morning. The target enrolment is approximately 120 subjects at approximately 20 study centres in Japan. The total duration of subject participation will be 54-55 weeks, consisting of a 7-14 day run-in period, 52-week treatment period and 1-week follow-up period. Subjects meeting all of the inclusion criteria and none of the exclusion criteria at screening visit (Visit 1) will enter 7-14 day run-in period. The run-in period is provided for completion of baseline safety evaluations and to obtain baseline measures of COPD status. Cardiovascular medical history/risk factors will be assessed at baseline. The following information will be collected from subjects receiving study medication and recorded in the eCRF: demography (including gender, ethnic origin and date of birth, height, weight), medical history (including duration of COPD and smoking history), COPD exacerbation assessment (documented history of ≥1 COPD exacerbation that required antibiotics/systemic corticosteroids or hospitalization in the past 12 months), concurrent medical conditions, and concomitant medication. At Visit 2, eligible subjects will start to take GSK573719/GW642444 125/25 mcg, and enter the treatment period. This treatment will be delivered via the Novel Dry Powder Inhaler (nDPI) once daily in the morning for 52 weeks. One nDPI will contain 30 doses of study medication. Subjects will be instructed to administer medication once daily in the morning for the duration of the 52-week treatment period. Each subject should be advised to adhere to this dosing regimen throughout the study. There will be a total of 8 study visits including at screening (Visit 1), initiation of treatment (Visit 2), and at 4weeks, 8 weeks, 12 weeks, 24 weeks, 36 weeks, 52 weeks (Visit 3 through Visit 8, respectively). Follow-up (Visit 9) will be conducted by the phone contact approximately 1 week following the completion/withdrawal of treatment period. A subject will be considered to have completed the study upon completion of the last on-treatment visit (Visit 8). At the end of the treatment period, subjects will be prescribed appropriate COPD medication at the investigator's discretion. Primary endpoint is incidence and severity of adverse events. Secondary endpoints are clinical laboratory tests (hematology, clinical chemistry), change from baseline in vital signs (pulse rate and systolic and diastolic pressure), and 12-lead Electrocardiogram (ECG) assessments. And other endpoints are change from baseline in trough Forced Expiratory Volume in One Second (FEV1) and Forced Vital Capacity (FVC), number of puffs of supplemental use of salbutamol, percentage of rescue-free days, percentage of symptom-free days, mean symptom scores, incidence of COPD exacerbations, and COPD device preference questionnaire.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
125/25mcg
Drug: GSK573719/GW642444 Inhalation Powder
Drug pages: GSK573719 · Vilanterol
GSK573719/GW642444 inhalation powder inhaled orally once daily for 52 weeks.
Number of Participants With Any Adverse Event (AE) and Any Serious Adverse Event (SAE) Throughout the Treatment Period
An AE is defined as any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in this definition, or is an event of possible drug-induced liver injury. Refer to the general AE/SAE module for a list of AEs (occuring at a frequency threshold of \>=5%) and SAEs.
Time frame: 52 weeks
Number of Participants With AEs Classified by the Indicated Maximum Grade Throughout the Treatment Period
An AE is defined as any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. AEs were classified according to intensity based upon the investigators' clinical judgment. The intensity was categorized as: mild (an event that is easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities); moderate (an event that is sufficiently discomforting to interfere with normal everyday activities); or severe (an event that prevents normal everyday activities).
Time frame: 52 weeks
Basophil, Eosinophil, Lymphocyte, Monocyte, and Total Neutrophil Values at Baseline (BL; Week -2), Week 12, Week 24, Week 52, the Withdrawal (WD) Visit, Week 24/WD, and Week 52/WD
Blood samples were collected for the measurement of the indicated laboratory parameters at following time points: BL (Week -2), Week 12, Week 24, Week 52, WD Visit (conducted for participants who withdrew at any point during the study), Week 24/WD (conducted for participants who completed the Week 24 visit or withdrew before Week 24), and Week 52/WD (conducted for participants who completed the Week 52 visit or withdrew before Week 52). The Baseline value for clinical laboratory tests was the value recorded on Week -2 (Screening visit).
Time frame: BL (Screening visit: Week -2), Week 12, Week 24, Week 52, WD Visit, Week 24/WD, and Week 52/WD
Eosinophil Values, Total Neutrophil Values, Platelet Count, and White Blood Cell (WBC) Count at Baseline (BL; Week -2), Week 12, Week 24, Week 52, the Withdrawal (WD) Visit, Week 24/WD, and Week 52/WD
Blood samples were collected for the measurment of the indicated laboratory parameters at the following time points: BL (Week -2), Week 12, Week 24, Week 52, WD Visit (conducted for participants who withdrew at any point during the study), Week 24/WD (conducted for participants who completed the Week 24 visit or withdrew before Week 24), and Week 52/WD (conducted for participants who completed the Week 52 visit or withdrew before Week 52). The Baseline value for clinical laboratory tests was the value recorded on Week -2 (Screening visit).
Time frame: BL (Screening visit: Week -2), Week 12, Week 24, Week 52, WD Visit, Week 24/WD, and Week 52/WD
Hemoglobin, Albumin, and Total Protein Values at Baseline (BL; Week -2), Week 12, Week 24, Week 52, the Withdrawal (WD) Visit, Week 24/WD, and Week 52/Withdrawal (WD)
Blood samples were collected for the measurement of hemoglobin, albumin, and total protein at the following time points: BL (Week -2), Week 12, Week 24, Week 52, WD Visit (conducted for participants who withdrew at any point during the study), Week 24/WD (conducted for participants who completed the Week 24 visit or withdrew before Week 24), and Week 52/WD (conducted for participants who completed the Week 52 visit or withdrew before Week 52). The Baseline value for clinical laboratory tests was the value recorded on Week -2 (Screening visit).
Time frame: BL (Screening visit: Week -2), Week 12, Week 24, Week 52, WD Visit, Week 24/WD, and Week 52/WD
Hematocrit Values at Baseline (BL; Week -2), Week 12, Week 24, Week 52, the Withdrawal (WD) Visit, Week 24/WD, and Week 52/WD
Blood samples were collected for the measurement of hematocrit at the following time points: BL (Week -2), Week 12, Week 24, Week 52, WD Visit (conducted for participants who withdrew at any point during the study), Week 24/WD (conducted for participants who completed the Week 24 visit or withdrew before Week 24), and Week 52/WD (conducted for participants who completed the Week 52 visit or withdrew before Week 52). The Baseline value for clinical laboratory tests was the value recorded on Week -2 (Screening visit).
Time frame: BL (Screening visit: Week -2), Week 12, Week 24, Week 52, WD Visit, Week 24/WD, and Week 52/WD
Alkaline Phosphatase (AP), Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), Creatine Kinase, and Gamma Glutamyl Transferase (GGT) Values at Baseline (BL; Week -2), Week 12, Week 24, Week 52, the WD Visit, Week 24/WD, and Week 52/WD
Blood samples were collected for the measurement of the indicated laboratory parameters at the following time points: BL (Week -2), Week 12, Week 24, Week 52, WD Visit (conducted for participants who withdrew at any point during the study), Week 24/WD (conducted for participants who completed the Week 24 visit or withdrew before Week 24), and Week 52/WD (conducted for participants who completed the Week 52 visit or withdrew before Week 52). The Baseline value for clinical laboratory tests was the value recorded on Week -2 (Screening visit).
Time frame: BL (Screening visit: Week -2), Week 12, Week 24, Week 52, WD Visit, Week 24/WD, and Week 52/WD
Direct Bilirubin, Indirect Bilirubin, Total Bilirubin, Creatinine, and Uric Acid Values at Baseline (BL; Week -2), Week 12, Week 24, Week 52, the WD Visit, Week 24/WD, and Week 52/WD
Blood samples were collected for the measuremnt of the indicated laboratory parameters at the following time points: BL (Week -2), Week 12, Week 24, Week 52, WD Visit (conducted for participants who withdrew at any point during the study), Week 24/WD (conducted for participants who completed the Week 24 visit or withdrew before Week 24), and Week 52/WD (conducted for participants who completed the Week 52 visit or withdrew before Week 52). The Baseline value for clinical laboratory tests was the value recorded on Week -2 (Screening visit).
Time frame: BL (Screening visit: Week -2), Week 12, Week 24, Week 52, WD Visit, Week 24/WD, and Week 52/WD
Calcium, Chloride, Glucose, Carbon Dioxide/Bicarbonate (CO2/HCO3), Potassium, Sodium, Phosphorous Inorganic, and Urea/Blood Urea Nitrogen (Urea/BUN) Values at Baseline (BL; Week -2), Week 12, Week 24, Week 52, WD Visit, Week 24/WD, and Week 52/WD
Blood samples were collected for the measurement of the indicated laboratory parameters at the following time points: BL (Week -2), Week 12, Week 24, Week 52, WD Visit (conducted for participants who withdrew at any point during the study), Week 24/WD (conducted for participants who completed the Week 24 visit or withdrew before Week 24), and Week 52/WD (conducted for participants who completed the Week 52 visit or withdrew before Week 52). The Baseline value for clinical laboratory tests was the value recorded on Week -2 (Screening visit).
Time frame: BL (Screening visit: Week -2), Week 12, Week 24, Week 52, WD Visit, Week 24/WD, and Week 52/WD
Change From Baseline in Blood Pressure
Blood pressure measurements included systolic blood pressure (SBP) and diastolic blood pressure (DBP). Blood pressure was measured in a sitting position after the participant was kept at rest for at least 5 minutes. Change from Baseline was calculated as the assessment value at the time of interest minus the Baseline value. The WD visit was conducted for participants who withdrew at any point during the study. The Week 24/WD visit was conducted for participants who completed the Week 24 visit or withdrew before Week 24. The Week 52/WD visit was conducted for participants who completed the Week 52 visit or withdrew before Week 52.
Time frame: Baseline (Week 0), Week 4, Week 8, Week 12, Week 24, Week 36, Week 52, WD Visit, Week 24/WD, and Week 52/WD
Change From Baseline in Heart Rate
Heart rate was measured in a sitting position after the participant was kept at rest for at least 5 minutes. Change from Baseline was calculated as the assessment value at the time of interest minus the Baseline value. The WD visit was conducted for participants who withdrew at any point during the study. The Week 24/WD visit was conducted for participants who completed the Week 24 visit or withdrew before Week 24. The Week 52/WD visit was conducted for participants who completed the Week 52 visit or withdrew before Week 52.
Time frame: Baseline (Week 0), Week 4, Week 8, Week 12, Week 24, Week 36, Week 52, WD Visit, Week 24/WD, and Week 52/WD
Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) Findings at the Indicated Time Points
A 12-lead ECG was recorded in a supine position after the participant was kept at rest in this position for at least 5 minutes. Data are presented as clinically significant (CS) or not clinically significant (NCS) abnormal findings. An abnormal and significant ECG finding includes the presence of a QT interval corrected for heart rate (QTc interval) \>500 milliseconds (msec) or an uncorrected QT interval \>600 msec, for participants with Bundle Branch Block QTc \>530 msec based on an average QTc value of triplicate ECGs. The study investigator determined if the abnormal ECG finding was CS or NCS. The WD visit was conducted for participants who withdrew at any point during the study. The Week 24/WD and Week 52/WD visits were conducted for participants who completed the Week 24 visit or withdrew before Week 24 and completed the Week 52 visit or withdrew before Week 52, respectively. The Baseline value for clinical laboratory tests was the value recorded on Week -2 (Screening visit).
Time frame: Baseline (Screening visit: Week -2), Week 12, Week 24, Week 36, Week 52, WD Visit, Week 24/WD, and Week 52/WD
131 participants (par.) comprised the All Subjects Enrolled Population (ASEP; all par. with records in the study database). One par. in the ASEP was withdrawn due to a Good Clinical Practice violation and was thus withdrawn from the Intent-to-Treat Population (comprised of all participants who received at least one dose of study drug; n=130).
| Milestone | UMEC/VI 125/25 µg |
|---|---|
| Started | 130 |
| Completed | 112 |
| Not completed | 18 |
| Withdrew: Adverse event | 13 |
| Withdrew: Lack of efficacy | 2 |
| Withdrew: Withdrawal by subject | 3 |
An AE is defined as any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in this definition, or is an event of possible drug-induced liver injury. Refer to the general AE/SAE module for a list of AEs (occuring at a frequency threshold of \>=5%) and SAEs.
| Participants | UMEC/VI 125/25 µg |
|---|---|
| Any AE | 113 |
| Any SAE | 16 |
An AE is defined as any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. AEs were classified according to intensity based upon the investigators' clinical judgment. The intensity was categorized as: mild (an event that is easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities); moderate (an event that is sufficiently discomforting to interfere with normal everyday activities); or severe (an event that prevents normal everyday activities).
| Participants | UMEC/VI 125/25 µg |
|---|---|
| Mild | 83 |
| Moderate | 20 |
| Severe | 10 |
Blood samples were collected for the measurement of the indicated laboratory parameters at following time points: BL (Week -2), Week 12, Week 24, Week 52, WD Visit (conducted for participants who withdrew at any point during the study), Week 24/WD (conducted for participants who completed the Week 24 visit or withdrew before Week 24), and Week 52/WD (conducted for participants who completed the Week 52 visit or withdrew before Week 52). The Baseline value for clinical laboratory tests was the value recorded on Week -2 (Screening visit).
| Percentage of cells in blood | UMEC/VI 125/25 µg |
|---|---|
| Basophils, BL (Week -2), n=130 | 0.54 ± 0.340 |
| Basophils, Week 12, n=127 | 0.58 ± 0.424 |
| Basophils, Week 24, n=122 | 0.59 ± 0.386 |
| Basophils, Week 52, n=112 | 0.60 ± 0.615 |
| Basophils, WD Visit, n=10 | 0.35 ± 0.246 |
| Basophils, Week 24/WD, n=129 | 0.58 ± 0.382 |
| Basophils, Week 52/WD, n=122 | 0.58 ± 0.597 |
| Eosinophils, BL (Week -2), n=130 | 3.90 ± 3.752 |
| Eosinophils, Week 12, n=127 | 3.73 ± 3.178 |
| Eosinophils, Week 24, n=122 | 4.07 ± 4.694 |
| Eosinophils, Week 52, n=112 | 3.54 ± 2.936 |
| Eosinophils, WD Visit, n=10 | 2.10 ± 1.662 |
| Eosinophils, Week 24/WD, n=129 | 3.97 ± 4.593 |
| Eosinophils, Week 52/WD, n=122 | 3.42 ± 2.876 |
| Lymphocytes, BL (Week -2), n=130 | 29.07 ± 8.471 |
| Lymphocytes, Week 12, n=127 | 28.48 ± 7.703 |
| Lymphocytes, Week 24, n=122 | 28.40 ± 8.620 |
| Lymphocytes, Week 52, n=112 | 28.71 ± 7.906 |
| Lymphocytes, WD Visit, n=10 | 21.28 ± 8.110 |
| Lymphocytes, Week 24/WD, n=129 | 28.12 ± 8.636 |
| Lymphocytes, Week 52/WD, n=122 | 28.10 ± 8.150 |
| Monocytes, BL (Week -2), n=130 | 6.15 ± 1.758 |
| Monocytes, Week 12, n=127 | 6.33 ± 1.727 |
| Monocytes, Week 24, n=122 | 6.27 ± 1.541 |
| Monocytes, Week 52, n=112 | 6.20 ± 1.827 |
| Monocytes, WD Visit, n=10 | 7.44 ± 1.290 |
| Monocytes, Week 24/WD, n=129 | 6.32 ± 1.541 |
| Monocytes, Week 52/WD, n=122 | 6.30 ± 1.818 |
| Total Neutrophils, BL (Week -2), n=130 | 60.34 ± 9.047 |
| Total Neutrophils, Week 12, n=127 | 60.88 ± 8.880 |
| Total Neutrophils, Week 24, n=122 | 60.67 ± 9.595 |
| Total Neutrophils, Week 52, n=112 | 60.96 ± 8.714 |
| Total Neutrophils, WD Visit, n=10 | 68.83 ± 8.296 |
| Total Neutrophils, Week 24/WD, n=129 | 61.01 ± 9.538 |
| Total Neutrophils, Week 52/WD, n=122 | 61.60 ± 8.915 |
Blood samples were collected for the measurment of the indicated laboratory parameters at the following time points: BL (Week -2), Week 12, Week 24, Week 52, WD Visit (conducted for participants who withdrew at any point during the study), Week 24/WD (conducted for participants who completed the Week 24 visit or withdrew before Week 24), and Week 52/WD (conducted for participants who completed the Week 52 visit or withdrew before Week 52). The Baseline value for clinical laboratory tests was the value recorded on Week -2 (Screening visit).
| 10^9 cells/Liter (GI/L) | UMEC/VI 125/25 µg |
|---|---|
| Eosinophils, BL (Week -2), n=130 | 0.245 ± 0.2324 |
| Eosinophils, Week 12, n=127 | 0.225 ± 0.1815 |
| Eosinophils, Week 24, n=122 | 0.260 ± 0.3243 |
| Eosinophils, Week 52, n=112 | 0.219 ± 0.1992 |
| Eosinophils, WD Visit, n=10 | 0.135 ± 0.1031 |
| Eosinophils, Week 24/WD, n=129 | 0.254 ± 0.3171 |
| Eosinophils, Week 52/WD, n=122 | 0.212 ± 0.1942 |
| Total Neutrophils, BL (Week -2), n=130 | 3.874 ± 1.2587 |
| Total Neutrophils, Week 12, n=127 | 3.798 ± 1.2169 |
| Total Neutrophils, Week 24, n=122 | 3.946 ± 1.5517 |
| Total Neutrophils, Week 52, n=112 | 3.899 ± 1.5434 |
| Total Neutrophils, WD Visit, n=10 | 4.860 ± 2.0869 |
| Total Neutrophils, Week 24/WD, n=129 | 3.953 ± 1.5326 |
| Total Neutrophils, Week 52/WD, n=122 | 3.978 ± 1.6060 |
| Platelet Count, BL (Week -2), n=130 | 234.3 ± 54.92 |
| Platelet Count, Week 12, n=127 | 238.6 ± 56.35 |
| Platelet Count, Week 24, n=122 | 239.3 ± 59.54 |
| Platelet Count, Week 52, n=112 | 233.8 ± 58.63 |
| Platelet Count, WD Visit, n=10 | 232.0 ± 84.03 |
| Platelet Count, Week 24/WD, n=129 | 240.0 ± 60.02 |
| Platelet Count, Week 52/WD, n=122 | 233.6 ± 60.65 |
| WBC Count, BL (Week -2), n=130 | 6.38 ± 1.588 |
| WBC Count, Week 12, n=127 | 6.18 ± 1.443 |
| WBC Count, Week 24, n=122 | 6.39 ± 1.803 |
| WBC Count, Week 52, n=112 | 6.30 ± 1.892 |
| WBC Count, WD Visit, n=10 | 6.88 ± 2.203 |
| WBC Count, Week 24/WD, n=129 | 6.37 ± 1.778 |
| WBC Count, Week 52/WD, n=122 | 6.35 ± 1.916 |
Blood samples were collected for the measurement of hemoglobin, albumin, and total protein at the following time points: BL (Week -2), Week 12, Week 24, Week 52, WD Visit (conducted for participants who withdrew at any point during the study), Week 24/WD (conducted for participants who completed the Week 24 visit or withdrew before Week 24), and Week 52/WD (conducted for participants who completed the Week 52 visit or withdrew before Week 52). The Baseline value for clinical laboratory tests was the value recorded on Week -2 (Screening visit).
| Grams/Liter (G/L) | UMEC/VI 125/25 µg |
|---|---|
| Hemoglobin, BL (Week -2), n=130 | 145.1 ± 13.35 |
| Hemoglobin, Week 12, n=127 | 148.2 ± 13.02 |
| Hemoglobin, Week 24, n=122 | 148.1 ± 13.58 |
| Hemoglobin, Week 52, n=112 | 148.2 ± 14.02 |
| Hemoblobin, WD Visit, n=10 | 146.6 ± 12.82 |
| Hemoglobin, Week 24/WD, n=129 | 148.0 ± 13.53 |
| Hemoglobin, Week 52/WD, n=122 | 148.0 ± 13.88 |
| Albumin, BL (Week -2), n=130 | 42.5 ± 2.58 |
| Albumin, Week 12, n=127 | 42.9 ± 2.44 |
| Albumin, Week 24, n=122 | 42.4 ± 2.76 |
| Albumin, Week 52, n=112 | 41.9 ± 2.96 |
| Albumin, WD Visit, n=10 | 41.3 ± 3.68 |
| Albumin, Week 24/WD, n=129 | 42.3 ± 2.80 |
| Albumin, Week 52/WD, n=122 | 41.9 ± 3.01 |
| Total Protein, BL (Week -2), n=130 | 70.9 ± 4.20 |
| Total Protein, Week 12, n=127 | 71.8 ± 4.50 |
| Total Protein, Week 24, n=122 | 71.2 ± 4.20 |
| Total Protein, Week 52, n=112 | 70.8 ± 4.78 |
| Total Protein, WD Visit, n=10 | 68.7 ± 5.46 |
| Total Protein, Week 24/WD, n=129 | 71.0 ± 4.22 |
| Total Protein, Week 52/WD, n=122 | 70.6 ± 4.85 |
Blood samples were collected for the measurement of hematocrit at the following time points: BL (Week -2), Week 12, Week 24, Week 52, WD Visit (conducted for participants who withdrew at any point during the study), Week 24/WD (conducted for participants who completed the Week 24 visit or withdrew before Week 24), and Week 52/WD (conducted for participants who completed the Week 52 visit or withdrew before Week 52). The Baseline value for clinical laboratory tests was the value recorded on Week -2 (Screening visit).
| Proportion | UMEC/VI 125/25 µg |
|---|---|
| BL (Week -2), n=130 | 0.4460 ± 0.03857 |
| Week 12, n=127 | 0.4534 ± 0.03575 |
| Week 24, n=122 | 0.4515 ± 0.03720 |
| Week 52, n=112 | 0.4517 ± 0.04063 |
| WD Visit, n=10 | 0.4473 ± 0.03970 |
| Week 24/WD, n=129 | 0.4512 ± 0.03724 |
| Week 52/WD, n=122 | 0.4513 ± 0.04041 |
Blood samples were collected for the measurement of the indicated laboratory parameters at the following time points: BL (Week -2), Week 12, Week 24, Week 52, WD Visit (conducted for participants who withdrew at any point during the study), Week 24/WD (conducted for participants who completed the Week 24 visit or withdrew before Week 24), and Week 52/WD (conducted for participants who completed the Week 52 visit or withdrew before Week 52). The Baseline value for clinical laboratory tests was the value recorded on Week -2 (Screening visit).
| International Units/Liter (IU/L) | UMEC/VI 125/25 µg |
|---|---|
| AP, BL (Week -2), n=130 | 242.1 ± 80.70 |
| AP, Week 12, n=127 | 250.2 ± 82.01 |
| AP, Week 24, n=122 | 257.3 ± 81.40 |
| AP, Week 52, n=112 | 247.5 ± 77.43 |
| AP, WD Visit, n=10 | 227.7 ± 74.24 |
| AP, Week 24/WD, n=129 | 254.2 ± 80.75 |
| AP, Week 52/WD, n=122 | 245.9 ± 77.07 |
| ALT, BL (Week -2), n=130 | 20.0 ± 10.42 |
| ALT, Week 12, n=127 | 21.9 ± 13.19 |
| ALT, Week 24, n=122 | 20.8 ± 13.06 |
| ALT, Week 52, n=112 | 21.2 ± 12.09 |
| ALT, WD Visit, n=10 | 31.7 ± 28.79 |
| ALT, Week 24/WD, n=129 | 21.1 ± 13.56 |
| ALT, Week 52/WD, n=122 | 22.0 ± 14.29 |
| AST, BL (Week -2), n=130 | 23.4 ± 7.35 |
| AST, Week 12, n=127 | 25.0 ± 8.90 |
| AST, Week 24, n=122 | 23.9 ± 9.62 |
| AST, Week 52, n=112 | 24.3 ± 8.94 |
| AST, WD Visit, n=10 | 41.1 ± 42.05 |
| AST, Week 24/WD, n=129 | 24.7 ± 14.48 |
| AST, Week 52/WD, n=122 | 25.7 ± 15.04 |
| Creatine Kinase, BL (Week -2), n=130 | 114.1 ± 59.56 |
| Creatine Kinase, Week 12, n=127 | 120.3 ± 111.89 |
| Creatine Kinase, Week 24, n=122 | 100.8 ± 42.60 |
| Creatine Kinase, Week 52, n=112 | 111.3 ± 59.60 |
| Creatine Kinase, WD Visit, n=10 | 387.5 ± 971.63 |
| Creatine Kinase, Week 24/WD, n=129 | 124.0 ± 271.90 |
| Creatine Kinase, Week 52/WD, n=122 | 134.0 ± 281.54 |
| GGT, BL (Week -2), n=130 | 47.1 ± 54.80 |
| GGT, Week 12, n=127 | 49.1 ± 57.91 |
| GGT, Week 24, n=122 | 49.1 ± 63.21 |
| GGT, Week 52, n=112 | 53.9 ± 78.30 |
| GGT, WD Visit, n=10 | 46.3 ± 26.29 |
| GGT, Week 24/WD Visit, n=129 | 49.2 ± 61.82 |
| GGT, Week 52/WD Visit, n=122 | 53.3 ± 75.37 |
Blood samples were collected for the measuremnt of the indicated laboratory parameters at the following time points: BL (Week -2), Week 12, Week 24, Week 52, WD Visit (conducted for participants who withdrew at any point during the study), Week 24/WD (conducted for participants who completed the Week 24 visit or withdrew before Week 24), and Week 52/WD (conducted for participants who completed the Week 52 visit or withdrew before Week 52). The Baseline value for clinical laboratory tests was the value recorded on Week -2 (Screening visit).
| Micromoles/Liter (µM/L) | UMEC/VI 125/25 µg |
|---|---|
| Direct Bilirubin, BL (Week -2), n=130 | 3.736 ± 1.7659 |
| Direct Bilirubin, Week 12, n=127 | 3.514 ± 1.6731 |
| Direct Bilirubin, Week 24, n=122 | 3.350 ± 1.4975 |
| Direct Bilirubin, Week 52, n=112 | 3.680 ± 1.6426 |
| Direct Bilirubin, WD Visit, n=10 | 3.249 ± 0.5407 |
| Direct Bilirubin, Week 24/WD, n=129 | 3.340 ± 1.4632 |
| Direct Bilirubin, Week 52/WD, n=122 | 3.644 ± 1.5846 |
| Indirect Bilirubin, BL (Week -2), n=130 | 7.064 ± 2.8991 |
| Indirect Bilirubin, Week 12, n=127 | 6.975 ± 2.7725 |
| Indirect Bilirubin, Week 24, n=122 | 6.728 ± 2.5424 |
| Indirect Bilirubin, Week 52, n=112 | 7.008 ± 2.9302 |
| Indirect Bilirubin, WD Visit, n=10 | 5.985 ± 2.4517 |
| Indirect Bilirubin, Week 24/WD, n=129 | 6.641 ± 2.5348 |
| Indirect Bilirubin, Week 52/WD, n=122 | 6.924 ± 2.8987 |
| Total Bilirubin, BL (Week -2), n=130 | 10.799 ± 4.3585 |
| Total Bilirubin, Week 12, n=127 | 10.489 ± 4.1067 |
| Total Bilirubin, Week 24, n=122 | 10.078 ± 3.6643 |
| Total Bilirubin, Week 52, n=112 | 10.687 ± 4.2603 |
| Total Bilirubin, WD Visit, n=10 | 9.234 ± 2.8156 |
| Total Bilirubin, Week 24/WD, n=129 | 9.982 ± 3.6261 |
| Total Bilirubin, Week 52/WD, n=122 | 10.568 ± 4.1714 |
| Creatinine, BL (Week -2), n=130 | 74.3036 ± 19.60971 |
| Creatinine, Week 12, n=127 | 74.3047 ± 19.32910 |
| Creatinine, Week 24, n=122 | 73.2633 ± 18.90496 |
| Creatinine, Week 52, n=112 | 75.6609 ± 18.69402 |
| Creatinine, WD Visit, n=10 | 71.8692 ± 10.60022 |
| Creatinine, Week 24/WD, n=129 | 73.2692 ± 18.55960 |
| Creatinine, Week 52/WD, n=122 | 75.3501 ± 18.16682 |
| Uric Acid, BL (Week -2), n=130 | 357.8408 ± 81.73895 |
| Uric Acid, Week 12, n=127 | 353.2737 ± 81.17581 |
| Uric Acid, Week 24, n=122 | 348.2993 ± 80.93244 |
| Uric Acid, Week 52, n=112 | 353.2687 ± 89.55111 |
| Uric Acid, WD Visit, n=10 | 343.7944 ± 87.40840 |
| Uric Acid, Week 24/WD, n=129 | 349.1799 ± 80.95415 |
| Uric Acid, Week 52, n=122 | 352.4921 ± 89.06027 |
Blood samples were collected for the measurement of the indicated laboratory parameters at the following time points: BL (Week -2), Week 12, Week 24, Week 52, WD Visit (conducted for participants who withdrew at any point during the study), Week 24/WD (conducted for participants who completed the Week 24 visit or withdrew before Week 24), and Week 52/WD (conducted for participants who completed the Week 52 visit or withdrew before Week 52). The Baseline value for clinical laboratory tests was the value recorded on Week -2 (Screening visit).
| Millimoles/Liter (MMOL/L) | UMEC/VI 125/25 µg |
|---|---|
| Calcium, BL (Week -2), n=130 | 2.2954 ± 0.09315 |
| Calcium, Week 12, n=127 | 2.2948 ± 0.09903 |
| Calcium, Week 24, n=122 | 2.2837 ± 0.09096 |
| Calcium, Week 52, n=112 | 2.2765 ± 0.09993 |
| Calcium, WD Visit, n=10 | 2.2829 ± 0.15878 |
| Calcium, Week 24/WD, n=129 | 2.2842 ± 0.09439 |
| Calcium, Week 52/WD, n=122 | 2.2770 ± 0.10506 |
| Chloride, BL (Week -2), n=130 | 103.7 ± 2.65 |
| Chloride, Week 12, n=127 | 105.7 ± 2.51 |
| Chloride, Week 24, n=122 | 105.7 ± 2.70 |
| Chloride, Week 52, n=112 | 105.5 ± 2.93 |
| Chloride, WD Visit, n=10 | 104.2 ± 3.65 |
| Chloride, Week 24/WD, n=129 | 105.6 ± 2.79 |
| Chloride, Week 52/WD, n=122 | 105.4 ± 3.00 |
| Glucose, BL (Week -2), n=130 | 6.4447 ± 1.86640 |
| Glucose, Week 12, n=127 | 6.3343 ± 1.63238 |
| Glucose, Week 24, n=122 | 6.7313 ± 2.20449 |
| Glucose, Week 52, n=112 | 6.6325 ± 1.81891 |
| Glucose, WD Visit, n=10 | 6.5280 ± 1.52070 |
| Glucose, Week 24/WD, n=129 | 6.7085 ± 2.15445 |
| Glucose, Week 52/WD, n=122 | 6.6239 ± 1.79105 |
| CO2/HCO3, BL (Week -2), n=130 | 25.7 ± 2.32 |
| CO2/HCO3, Week 12, n=127 | 25.1 ± 2.29 |
| CO2/HCO3, Week 24, n=122 | 24.1 ± 2.31 |
| CO2/HCO3, Week 52, n=112 | 23.8 ± 2.18 |
| CO2/HCO3, WD Visit, n=10 | 24.3 ± 3.50 |
| CO2/HCO3, Week 24/WD, n=129 | 24.2 ± 2.41 |
| CO2/HCO3, Week 52/WD, n=122 | 23.9 ± 2.30 |
| Potassium, BL (Week -2), n=130 | 4.29 ± 0.380 |
| Potassium, Week 12, n=127 | 4.34 ± 0.384 |
| Potassium, Week 24, n=122 | 4.33 ± 0.374 |
| Potassium, Week 52, n=112 | 4.31 ± 0.362 |
| Potassium, WD Visit, n=10 | 4.42 ± 0.301 |
| Potassium, Week 24/WD, n=129 | 4.33 ± 0.366 |
| Potassium, Week 52/WD, n=122 | 4.32 ± 0.357 |
| Sodium, BL (Week -2), n=130 | 141.4 ± 2.09 |
| Sodium, Week 12, n=127 | 142.3 ± 1.95 |
| Sodium, Week 24, n=122 | 142.3 ± 2.03 |
| Sodium, Week 52, n=112 | 141.4 ± 2.26 |
| Sodium, WD Visit, n=10 | 140.4 ± 3.72 |
| Sodium, Week 24/WD, n=129 | 142.2 ± 2.21 |
| Sodium, Week 52/WD, n=122 | 141.4 ± 2.41 |
| Phosphorous Inorganic, BL (Week -2), n=130 | 0.9714 ± 0.15901 |
| Phosphorous Inorganic, Week 12, n=127 | 1.0124 ± 0.16447 |
| Phosphorous Inorganic, Week 24, n=122 | 0.9975 ± 0.16216 |
| Phosphorous Inorganic, Week 52, n=112 | 0.9448 ± 0.16492 |
| Phosphorous Inorganic, WD Visit, n=10 | 0.9913 ± 0.17558 |
| Phosphorous Inorganic, Week 24/WD, n=129 | 0.9985 ± 0.16349 |
| Urea/BUN, BL (Week -2), n=130 | 0.9486 ± 0.16555 |
| Phosphorous Inorganic, Week 52/WD, n=122 | 5.2660 ± 1.52578 |
| Urea/BUN, Week 12, n=127 | 5.4764 ± 1.80029 |
| Urea/BUN, Week 24, n=122 | 5.4998 ± 1.50802 |
| Urea/BUN, Week 52, n=112 | 5.4570 ± 1.66582 |
| Urea/BUN, WD Visit, n=10 | 5.4335 ± 2.05521 |
| Urea/BUN, Week 24/WD, n=129 | 5.4856 ± 1.52903 |
| Urea/BUN, Week 52/WD, n=122 | 5.4551 ± 1.69111 |
Blood pressure measurements included systolic blood pressure (SBP) and diastolic blood pressure (DBP). Blood pressure was measured in a sitting position after the participant was kept at rest for at least 5 minutes. Change from Baseline was calculated as the assessment value at the time of interest minus the Baseline value. The WD visit was conducted for participants who withdrew at any point during the study. The Week 24/WD visit was conducted for participants who completed the Week 24 visit or withdrew before Week 24. The Week 52/WD visit was conducted for participants who completed the Week 52 visit or withdrew before Week 52.
| Millimeters of Mercury (mmHg) | UMEC/VI 125/25 µg |
|---|---|
| SBP, Week 4, n=128 | 1.1 ± 12.27 |
| SBP, Week 8, n=127 | 2.0 ± 13.79 |
| SBP, Week 12, n=127 | 2.5 ± 13.62 |
| SBP, Week 24, n=122 | 2.7 ± 14.80 |
| SBP, Week 36, n=116 | -3.3 ± 13.80 |
| SBP, Week 52, n=112 | 0.4 ± 13.82 |
| SBP, WD Visit, n=10 | -2.3 ± 18.62 |
| SBP, Week 24/WD, n=129 | 2.5 ± 15.09 |
| SBP, Week 52/WD, n=122 | 0.2 ± 14.19 |
| DBP, Week 4, n=128 | 1.0 ± 9.21 |
| DBP, Week 8, n=127 | 1.4 ± 9.99 |
| DBP, Week 12, n=127 | 0.9 ± 10.71 |
| DBP, Week 24, n=122 | 0.9 ± 10.81 |
| DBP, Week 36, n=116 | -1.5 ± 11.10 |
| DBP, Week 52, n=112 | 0.6 ± 10.23 |
| DBP, WD Visit, n=10 | -2.0 ± 11.05 |
| DBP, Week 24/WD, n=129 | 0.6 ± 10.92 |
| DBP, Week 52/WD, n=122 | 0.4 ± 10.28 |
Heart rate was measured in a sitting position after the participant was kept at rest for at least 5 minutes. Change from Baseline was calculated as the assessment value at the time of interest minus the Baseline value. The WD visit was conducted for participants who withdrew at any point during the study. The Week 24/WD visit was conducted for participants who completed the Week 24 visit or withdrew before Week 24. The Week 52/WD visit was conducted for participants who completed the Week 52 visit or withdrew before Week 52.
| Beats per minute | UMEC/VI 125/25 µg |
|---|---|
| Week 4, n=128 | -0.7 ± 10.21 |
| Week 8, n=127 | -0.7 ± 9.39 |
| Week 12, n=127 | -1.4 ± 10.81 |
| Week 24, n=122 | -0.5 ± 10.63 |
| Week 36, n=116 | -2.2 ± 10.56 |
| Week 52, n=112 | -0.7 ± 10.63 |
| WD Visit, n=10 | 9.0 ± 10.46 |
| Week 24/WD, n=129 | -0.1 ± 10.67 |
| Week 52/WD, n=122 | 0.1 ± 10.90 |
A 12-lead ECG was recorded in a supine position after the participant was kept at rest in this position for at least 5 minutes. Data are presented as clinically significant (CS) or not clinically significant (NCS) abnormal findings. An abnormal and significant ECG finding includes the presence of a QT interval corrected for heart rate (QTc interval) \>500 milliseconds (msec) or an uncorrected QT interval \>600 msec, for participants with Bundle Branch Block QTc \>530 msec based on an average QTc value of triplicate ECGs. The study investigator determined if the abnormal ECG finding was CS or NCS. The WD visit was conducted for participants who withdrew at any point during the study. The Week 24/WD and Week 52/WD visits were conducted for participants who completed the Week 24 visit or withdrew before Week 24 and completed the Week 52 visit or withdrew before Week 52, respectively. The Baseline value for clinical laboratory tests was the value recorded on Week -2 (Screening visit).
| Participants | UMEC/VI 125/25 µg |
|---|---|
| BL (Week -2), Abnormal NCS, n=130 | 45 |
| BL (Week -2), Abnormal CS, n=130 | 2 |
| Week 12, Abnormal NCS, n=127 | 50 |
| Week 12, Abnormal CS, n=127 | 2 |
| Week 24, Abnormal NCS, n=122 | 43 |
| Week 24, Abnormal CS, n=122 | 3 |
| Week 36, Abnormal NCS, n=116 | 45 |
| Week 36, Abnormal CS, n=116 | 2 |
| Week 52, Abnormal NCS, n=112 | 47 |
| Week 52, Abnormal CS, n=112 | 2 |
| WD Visit, Abnormal NCS, n=9 | 4 |
| WD Visit, Abnormal CS, n=9 | 0 |
| Week 24/WD, Abnormal NCS, n=128 | 46 |
| Week 24/WD, Abnormal CS, n=128 | 3 |
| Week 52/WD, Abnormal NCS, n=121 | 51 |
| Week 52/WD, Abnormal CS, n=121 | 2 |
Collected over Serious adverse events (SAEs) and non-serious AEs were collected from the start of study medication until Follow-up (up to 53 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GSK573719/GW642444 | — | 16/130 (12.3%) | 70/130 (53.8%) |
| Event | GSK573719/GW642444 |
|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 5/130 |
| PneumoniaInfections and infestations | 3/130 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 1/130 |
| Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders | 1/130 |
| NasopharyngitisInfections and infestations | 1/130 |
| Pneumonia bacterialInfections and infestations | 1/130 |
| DysphagiaGastrointestinal disorders | 1/130 |
| Inguinal herniaGastrointestinal disorders | 1/130 |
| Radicular cystGastrointestinal disorders | 1/130 |
| Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/130 |
| Event | GSK573719/GW642444 |
|---|---|
| NasopharyngitisInfections and infestations | 49/130 |
| BronchitisInfections and infestations | 13/130 |
| PharyngitisInfections and infestations | 9/130 |
| ConstipationGastrointestinal disorders | 7/130 |
| Age, Continuous(Years) | UMEC/VI 125/25 µg |
|---|---|
| Mean | 70.4 ± 7.86 |
| Gender(Participants) | UMEC/VI 125/25 µg |
|---|---|
| Female | 10 |
| Male | 120 |
| Race/Ethnicity, Customized(Participants) | UMEC/VI 125/25 µg |
|---|---|
| Asian - Japanese Heritage | 130 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Aug 2011, a primary completion of Dec 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2014, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: GSK573719 · Vilanterol
Pulmonary Disease, Chronic Obstructive →